https://www.technologynetworks.com/drug-discovery/news/bioinvent-and-thrombogenics-start-recruitment-of-second-100-patient-cohort-in-phase-ii-dvt-prophylaxis-study-with-tb402-188359
The second cohort of trial follows advice from the external efficacy and safety monitoring board to proceed using a higher dose of TB-402.
bioinventstartrecruitmentsecondpatient